In continuation DMPK lecture series, ECBS community is presenting the last webinar for the year on December 15th, 2023 from 12-1:30pm EST. Please find the meeting details below.
The ECBS co-leads would also like to apologize for the confusion regarding the meeting link of the webinar on November 17th. If you were not able to attend that webinar, please reach out to [email protected] for a copy of the slide deck.
The webinar on December 15th is a continuation to the last session: scientists not versed in pharmacokinetics will be introduced to its key principles. We'll explore foundational PK topics such as clearance, exposures, and bioavailability, underscoring their significance in drug development. We'll give special attention to advanced concepts and their real-world applications.
Agenda:
12:00-12:15: Greetings and general announcements from ECBS community
12:15-1:15: DMPK lecture series Webinar#4 (presented by Bonnie and Jiangbo)
1:15-1:30: Q&A
Bonnie Wang is as an Associate Director in the clinical pharmacology division at Bristol-Myers Squibb (BMS). She serves as a clinical pharmacology lead in asset teams and governance discussions, offering crucial strategic guidance for designing clinical studies at various developmental phases. With over twenty years in the nonclinical drug development sector, her proficiency covers both small molecules and biologics, especially in the areas of DMPK and toxicology. Bonnie began her BMS tenure in 2004 after a notable four-year stint at Merck. Her educational background includes training in Molecular Biology and Nutrition. She has recently earned her MS in Pharmacometrics from the University of Maryland-Baltimore. Notably, she holds a diplomate certification from the American Board of Toxicology (DABT).
Jiangbo Tang is a Principal Scientist in the Department of Clinical Pharmacology, Pharmacometrics, Disposition & Bioanalysis at Bristol-Myers Squibb (BMS). He leads regulated PK and immunogenicity bioanalytical development to support programs in CAR T, ADC, and antibody therapeutics. Prior to joining BMS, for several years he led a team at a CRO and provided regulated bioanalytical support for clinical programs. He also worked as a Staff Scientist in the QC Department at Regeneron, where he automated potency assays in support of stability, and lot release of drug products. Jiangbo received his PhD in Human Genetics from the University of Pittsburgh and completed his postdoc training at the University of Pennsylvania, where his published research in cancer biology and immunology has been widely cited with over 1,500 citations.
____________________________________________________________________________
Microsoft Teams meeting
Join on your computer, mobile app or room device
Click here to join the meeting
Meeting ID: 258 944 169 537
Passcode: e9mYtb
Download Teams | Join on the web
Or call in (audio only)
+1 908-409-1059,,252311155# United States, Elizabeth
(833) 733-5876,,252311155# United States (Toll-free)
Phone Conference ID: 252 311 155#
Find a local number | Reset PIN
Audio for this meeting can be heard in the Microsoft Teams client. Please check your audio device settings before you join the call. If you see phone numbers above, you can use them to join the meeting's audio if necessary.
Learn More | 19_meeting_NTM0NzIzNDUtODY1Yy00ZjRlLTkwMDEtNGZkZDI0ZDI4ZjQ5@thread.v2&messageId=0&language=en-US" target="_blank" rel="noopener">Meeting options
------------------------------
Kelly Pham
Merck & Co
[email protected]Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------